— Know what they know.
Not Investment Advice

QMDT OTC

Quick-Med Technologies, Inc.
1W: +0.0% 1M: -37.5% 3M: -37.5% YTD: +400.0% 1Y: +400.0% 3Y: +0.0% 5Y: -94.6%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 46 · $18673 mcap · 31M float · 0.0002% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.0008
Volume135,000
Avg Volume48
Beta-0.82
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOGerald Reisman
Employees5
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2002-10-16
902 NW 4th Street
Gainesville, FL 32601
US
352-379-0611
About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. focuses on sustainable antimicrobial technologies. It provides treatment optimization, laboratory prototyping to factory scale-up, domestic and international regulatory guidance, microbiological efficacy testing including viruses, patent expertise, technology evaluations, antimicrobials market evaluations, and scientific invention and original research products. The company’s core technologies include Nimbus, a non-leaching antimicrobial wound dressing material; Stay Fresh, a sequestered hydrogen peroxide-based antimicrobial technology; and superabsorbent antimicrobial materials. In addition, it offers bioguard, DriGo-HP, antimicrobial care products, antimicrobial textiles, and antimicrobial paints and coatings products. Quick-Med Technologies, Inc. was incorporated in 1997 and is headquartered in Gainesville, Florida.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
PHRONESIS PARTNERS L S-Sale 10,100 $0.05 2013-02-07
PHRONESIS PARTNERS L S-Sale 0 — 2013-02-07
PHRONESIS PARTNERS L S-Sale 25,000 $0.05 2013-02-07
PHRONESIS PARTNERS L S-Sale 0 — 2013-02-07
PHRONESIS PARTNERS L S-Sale 0 — 2013-01-30

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms